ArticleScientific reports2026
A homoeriodictyol sodium mouthwash reduces bitterness sensitivity in patients with gynecological cancer receiving carboplatin-based chemotherapy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Bitter taste disorders are common chemotherapy-induced side effects that compromise nutrition and quality of life. Since no treatment exists for conditions such as bitter taste hypersensitivity and phantogeusia, we hypothesized that a homoeriodictyol sodium (Na-HED) mouthwash reduces chemotherapy-induced bitterness sensitivity caused by salivary platinum (Pt) species derived from intravenously administered carboplatin. In a clinical pilot study involving patients with gynecological cancer (n = 8) receiving carboplatin-based chemotherapy, dietary intake, salivary Pt concentrations, and changes in taste perception were investigated. Patients exhibited decreased energy and protein intake, and salivary Pt. Using an in vitro blood-saliva barrier model, the transfer of Pt-based agents, specifically carboplatin and cisplatin, was demonstrated. Standardized sensory testing in patients revealed increased bitter taste sensitivity compared with the chemo-naïve baseline. A rinse-and-spit solution containing Na-HED, an approved flavoring compound and antagonist of bitter taste receptors (TAS2Rs), reduced the perceived bitterness of caffeine in patients receiving carboplatin (n = 15). As various anticancer agents are predicted to bind to TAS2Rs, a prerequisite for bitter taste sensation, this bitter-masking strategy may have broader applicability. Our preliminary findings show that the Na-HED mouthwash reduces bitter taste sensitivity in patients, supporting its potential to alleviate chemotherapy-induced bitter taste hypersensitivity and phantogeusia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.